BioLineRx acquires Agalimmune to accelerate immuno-oncology pipeline

Thursday, March 23, 2017

BioLineRx, a clinical-stage biopharmaceutical company focused on oncology and immunology, has acquired Agalimmune, a private U.K.-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of which $3 million is in cash and the remainder in BioLineRx shares. Additional future payments may be made based on development and commercial milestones.

[Read More]